Investors take note: BioNxt Solutions builds on blockbusters from Novo Nordisk and Merck - and has another ace up its sleeve in oncology

Pillar 1: Cladribine ODF – The flagship candidate on the home stretch

BioNxt's lead project is BNT23001, a sublingual thin-film containing Merck's active ingredient Cladribine for the treatment of multiple sclerosis (MS). The approach is brilliant because it takes an already established and effective active ingredient and significantly improves it for the patient experience. Administration as a wafer-thin film under the tongue bypasses the digestive tract, increasing bioavailability and avoiding stressful passage through the liver. For MS patients, many of whom have difficulty swallowing, this represents a significant gain in comfort and is expected to greatly improve therapy adherence.

This pillar made tremendous progress in October. Most notably, BioNxt filed a "Track One" priority application for the US patent, which also covers other neurological autoimmune diseases. This accelerated process promises a final decision within just 9-12 months. A strong US patent is the ticket to the world's most lucrative pharmaceutical market and the most important lever for subsequent licensing negotiations with Big Pharma. At the same time, patent applications in Europe, Canada, and other key markets are already in full swing, with consistently positive feedback from the authorities.

At the same time, the Company is preparing for the final major hurdle before the start of human trials: a bioavailability study in large animals (pigs), which is scheduled to begin in October. Success here will pave the way for the first clinical trial in humans in the first quarter of 2026, traditionally the most value-driving milestone for a biotech company.

Pillar 2: Semaglutide ODF – Entering the GLP-1 megatrend

While all eyes are on the blockbuster injections from Novo Nordisk and Eli Lilly, BioNxt is quietly working on a disruptive alternative: an oral dissolvable film containing Semaglutide, the active ingredient in Ozempic and Wegovy. The advantages are clear. A needle-free, discreet, and easy-to-administer dosage form could revolutionize treatment adherence in a market estimated to be worth over USD 150 billion by 2030.

News reports from September and October indicate that this program is gaining momentum. The Company has secured the high-purity active ingredient and has already successfully tested the initial prototypes at its subsidiary, Vektor Pharma, in Germany. Internal assessments describe the results as "convincing," highlighting rapid dissolution and good mechanical properties. On this basis, BioNxt is now preparing to file a patent application and aims to transition the program to the preclinical phase later this year.

This second pillar is not a niche project, but directly targets the core of the fastest-growing pharmaceutical segment. If BioNxt succeeds in formulating Semaglutide in a stable and bioavailable film, it could unlock licensing opportunities that may even surpass those of the flagship project.

Pillar 3: Targeted chemotherapy platform – the disruptive lever

Beyond the dissolvable films, BioNxt is developing a potentially groundbreaking technology for oncology. The concept is to stop distributing chemotherapeutic agents systemically throughout the body, but to instead activate them specifically within the tumor. A dual mechanism concentrates the active ingredients at the target site while simultaneously neutralizing non-activated molecules in healthy tissue. In vitro data indicate up to a 10-fold increase in therapeutic efficacy with significantly reduced toxicity.

The October update on this was substantial. The research team has built a molecular database and identified a priority drug candidate ideally suited for a proof-of-concept study. This candidate is a clinically established chemotherapeutic agent which could further shorten the development timeline. Even more significant is the announcement that a definitive agreement for this platform will be signed in the "coming weeks", paving the way for the long-awaited partnership or financing for this highly disruptive branch.

The big picture: Scalability and calculated risk

BioNxt's true strength lies not in a single pillar, but in the combination of all three. It represents a well-thought-out risk diversification strategy. While the Cladribine pillar paves the commercial path in the short term, Semaglutide offers access to an unparalleled growth market. The chemo platform, in turn, is the long-term, disruptive lever that, if successful, could transform the entire oncology sector.

The company consistently follows the same, calculated approach. Instead of inventing entirely new active ingredients, it improves proven substances through intelligent delivery systems. This reduces typical biotech risks, including high costs, long development timelines, and the binary failure of untested molecules. The focus on licensing to pharmaceutical giants also makes the business model scalable and capital market efficient.

With a target price of EUR 2.50, analysts at Black Research see significant potential in the stock - a stark contrast to the current price of just CAD 0.86.

BioNxt Solutions is a strategically positioned company with three clearly defined and independent promising technology pillars. The concentrated progress made in October in patents, preclinical development, and partnerships underscores the Company's operational strength. For investors who want to take advantage of the opportunities offered by biotech but mitigate risks through a platform-based, scalable approach, BioNxt offers a compelling overall package. The coming months will reveal the potential of these three pillars.